Trial Search Results

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seattle Genetics, Inc.

Collaborator: Genentech, Inc.

Stanford Investigator(s):


  • Drug: SGN-40


Phase 2


Inclusion Criteria:

   - Diagnosis of DLBCL.

   - Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP,
   R-ESHAP or equivalent.

   - Progression or relapse since most recent therapy.

   - At least one measurable lesion that is both greater than or equal to 2 cm by
   conventional CT or greater than or equal to 1.5 cm by spiral CT.

Exclusion Criteria:

   - Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or
   central nervous system lymphoma.

   - Primary refractory disease.

   - Received an allogenic stem cell transplant.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ranjana Advani
Not Recruiting